Novartis Gene Therapies News

Work in Progress to Support Jobseekers and Identify New Candidates for Facility

Novartis Gene Therapies, formerly AveXis, plans to wind down its Longmont facility in July. Novartis Gene Therapies has been a great partner to Colorado BioScience Association. We want to recognize its team for taking an active role in our life sciences community. They have supported CBSA and provided leadership and financial support for the Colorado BioScience Institute.

While we are disappointed about this news, we understand the work of innovation requires flexibility and the ability to pivot.

The CBSA team is working with our economic development partners to connect the highly skilled Novartis Gene Therapies workforce to new job opportunities within Colorado’s life sciences ecosystem. With a

number of companies actively hiring, we anticipate those workers will land new jobs. It’s also a top priority to attract a new company for the Longmont facility.

Colorado’s life sciences ecosystem includes strong, thriving companies and organizations at all stages of commercialization, leading academic and research institutions, and a highly educated and skilled workforce. We have robust infrastructure to support life sciences innovation. Our ecosystem includes 33 federal labs, one of the largest concentrations in the country.

Companies want to make investments in communities with strong talent and infrastructure. That’s why companies at all stages of commercialization choose Colorado.

CBSA works to ensure Colorado is a competitive and attractive place for life sciences investment.

Categories: CBSA News